CompletedNCT00202293
Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features
Medication studyAges 15–29AustraliaBipolarity
Understand this study
Who was this study for?
Listed age limits: 15 years to 29 years.
- Listed locations
- ParkvilleSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateOctober 1, 2001
- Recruitment status
- Completed
- Enrollment listed in the registry
- 83
- Sponsor
- Melbourne Health
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Australia
- Age range
- From 15 Years to 29 Years
- Official registry ID
- NCT00202293
- Official title
Show the full official title
Comparison of Combination Olanzapine and Lithium and Combination Chlorpromazine and Lithium in the Treatment of a First Manic Episode With Psychotic Features.
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Parkville
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Melbourne Health.
Did this study involve medication?
Yes. The study involved medication, including Olanzapine, lithium and Chlorpromazine.
Who was this study for?
Listed age limits: 15 years to 29 years.
